Free Trial
→ A new type of AI could unleash gains of up to 10,000% (From Brownstone Research) (Ad)tc pixel
NASDAQ:NVCR

NovoCure Q3 2026 Earnings Report

NovoCure logo
$14.94 -0.98 (-6.16%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$15.07 +0.13 (+0.90%)
As of 10/2/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

NovoCure EPS Results

Actual EPS
N/A
Consensus EPS
-$0.24
Beat/Miss
N/A
One Year Ago EPS
N/A

NovoCure Revenue Results

Actual Revenue
N/A
Expected Revenue
$182.28 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

NovoCure Announcement Details

Quarter
Q3 2026
Date
10/29/2026
Time
Before Market Opens
Conference Call Date
Thursday, October 29, 2026
Conference Call Time
8:00AM ET

Conference Call Resources

NovoCure Earnings Headlines

Novocure’s Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
October 1 at 10:33 PM  |  marketscreener.comM
Novocure Receives Approval In Japan For Optune Pax For The Treatment Of Unresectable Locally Advanced Pancreatic Cancer
October 1 at 5:33 PM  |  marketscreener.comM
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt without major changes. As former head of the Department of Government Efficiency under President Trump, Musk saw firsthand how looming spending cuts could rattle markets and squeeze 401ks, IRAs, and TSPs. A preserved IRS provision may help everyday investors shield their retirement savings before the next wave of volatility hits.tc pixel
October 4 at 1:00 AM  |  American Hartford Gold (Ad)
NovoCure's Optune Pax Approved in Japan for Advanced Pancreatic Cancer
October 1 at 12:29 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/novocure-apos-optune-pax-approved-132813251.html
Novocure to Report Third Quarter 2026 Financial Results
October 1 at 7:29 AM  |  marketscreener.comM
Contrasting NovoCure (NASDAQ:NVCR) and Medtronic (NYSE:MDT)
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31058107
See More NovoCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovoCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your email.

About NovoCure

NovoCure (NASDAQ:NVCR) Ltd. (NASDAQ: NVCR) is an oncology company focused on developing and commercializing Tumor Treating Fields (TTFields), a non-invasive cancer treatment that uses low-intensity alternating electric fields to disrupt the division of tumor cells. The company’s technology is designed to be delivered through wearable systems that generate fields at specific frequencies and intensities.

NovoCure’s primary products include Optune Gio, marketed in the United States for certain adults with glioblastoma, and Optune Lua, approved in the United States for use with standard chemotherapy in adults with unresectable, locally advanced or metastatic malignant pleural mesothelioma. The company also has been evaluating TTFields in additional solid tumors, including non-small cell lung cancer, pancreatic cancer and ovarian cancer.

NovoCure was founded in 2000 by Professor Yoram Palti, who developed the TTFields approach. The company serves patients and healthcare providers in the United States and international markets, including Europe and Japan, and conducts clinical and commercial activities across multiple regions. Its corporate headquarters are in Baar, Switzerland.

View NovoCure Profile
Earnings Tools